Q1 EPS Forecast for Oric Pharmaceuticals Raised by Analyst

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) – HC Wainwright lifted their Q1 2026 earnings estimates for Oric Pharmaceuticals in a research note issued to investors on Tuesday, February 24th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of ($0.31) per share for the quarter, up from their prior estimate of ($0.37). HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Oric Pharmaceuticals’ current full-year earnings is ($2.17) per share. HC Wainwright also issued estimates for Oric Pharmaceuticals’ Q2 2026 earnings at ($0.32) EPS, Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at ($0.34) EPS and FY2026 earnings at ($1.28) EPS.

Oric Pharmaceuticals (NASDAQ:ORIC) last released its quarterly earnings results on Monday, February 23rd. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.04.

Other equities analysts have also recently issued reports about the company. Wedbush reissued an “outperform” rating and issued a $20.00 price target on shares of Oric Pharmaceuticals in a report on Tuesday. Wells Fargo & Company lifted their price objective on Oric Pharmaceuticals from $19.00 to $25.00 and gave the stock an “overweight” rating in a research report on Monday, December 8th. Wall Street Zen downgraded shares of Oric Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, November 23rd. Citigroup upped their target price on shares of Oric Pharmaceuticals from $16.00 to $17.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Wolfe Research assumed coverage on shares of Oric Pharmaceuticals in a research note on Tuesday, November 18th. They set a “peer perform” rating on the stock. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $20.20.

Oric Pharmaceuticals Stock Performance

ORIC stock opened at $13.40 on Thursday. The stock’s 50 day moving average price is $10.17 and its 200 day moving average price is $10.96. The firm has a market cap of $1.34 billion, a P/E ratio of -8.82 and a beta of 1.35. Oric Pharmaceuticals has a 1 year low of $3.90 and a 1 year high of $14.93.

Institutional Trading of Oric Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. AQR Capital Management LLC purchased a new position in shares of Oric Pharmaceuticals in the 1st quarter worth $276,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Oric Pharmaceuticals by 8.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,201 shares of the company’s stock valued at $226,000 after acquiring an additional 3,131 shares during the period. Goldman Sachs Group Inc. increased its stake in Oric Pharmaceuticals by 9.2% during the first quarter. Goldman Sachs Group Inc. now owns 294,784 shares of the company’s stock worth $1,645,000 after acquiring an additional 24,778 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Oric Pharmaceuticals by 1,331.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 509,179 shares of the company’s stock worth $2,841,000 after acquiring an additional 473,600 shares during the last quarter. Finally, Jane Street Group LLC raised its holdings in shares of Oric Pharmaceuticals by 56.0% in the 1st quarter. Jane Street Group LLC now owns 31,198 shares of the company’s stock worth $174,000 after purchasing an additional 11,198 shares during the period. 95.05% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Oric Pharmaceuticals

In related news, CEO Jacob Chacko sold 33,374 shares of the firm’s stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $9.06, for a total value of $302,368.44. Following the sale, the chief executive officer directly owned 581,711 shares of the company’s stock, valued at approximately $5,270,301.66. This trade represents a 5.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Dominic Piscitelli sold 10,720 shares of the business’s stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $9.06, for a total transaction of $97,123.20. Following the completion of the sale, the chief financial officer owned 68,148 shares of the company’s stock, valued at approximately $617,420.88. The trade was a 13.59% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 54,814 shares of company stock worth $496,615 in the last three months. Company insiders own 6.82% of the company’s stock.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.